MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
OpenAI Rejects Apple Trade Secret Theft Claims 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Shein Shares Slide 9% in Hong Kong IPO Debut 
Add as a preferred source on Google
LAWRENCEVILLE, N.J., March 12, 2018 -- -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Michael Tardugno, Chairman, President and Chief Executive Officer, will present at the following upcoming investor conferences:
- The B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS) on Friday, March 16, 2018 at 3:30 p.m. local time. The conference will be held March 15-17, 2018 at The InterContinental Hotel Hangzhou, China.
- The Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018 at 9:10 a.m. EDT. The conference will be held March 20-21, 2018 at The Westin New York Grand Central in New York City.
A live webcast of Celsion’s presentation at the Oppenheimer conference may be accessed by visiting the “News & Investors” section of Celsion’s corporate website at www.celsion.com. A replay of the webcast will also be available and archived on the site for 90 days following the presentation or until June 19, 2018.
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer. The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: www.celsion.com. (CLSN-FIN)
ThermoDox® is a registered trademark of Celsion Corporation.
Celsion Investor Contact Jeffrey W. Church Sr. Vice President and CFO 609-482-2455 [email protected]
